Find Funding Opportunities

Find Funding Opportunities

Subscribe to Find Funding OpportunitiesRSS
Returning 1516 results

Notice of Change to Key Dates of RFA-MH-21-175, "BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed)"

NOT
Tuesday, September 21, 2021
Thursday, June 8, 2023
NOT-MH-21-345

Funding Opportunity Purpose

This Notice modifies key dates of RFA-MH-21-175.

Notice of Change to NOT-NS-20-038 "Notice of Special Interest: Administrative Supplement for the NINDS Research Education Program for Residents and Fellows in Neurology, Neurosurgery, Neuropathology, Neuroradiology and Emergency Medicine (Admin Supp)"

NOT
Tuesday, September 21, 2021
Monday, January 1, 2024
NOT-NS-22-027

Funding Opportunity Purpose

The purpose of this notice is to update the Funding Opportunity Announcement (FOA) used to solicit applications through NOT-NS-20-038 "Notice of Special Interest (NOSI): Administrative Supplement for the NINDS Research Education Program for Residents and Fellows in Neurology, Neurosurgery, Neuropathology, Neuroradiology and Emergency Medicine (Admin Supp)". The Parent Administrative Supplement PA-18-591 "Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)" has expired. It has been reissued as PA-20-272 "https://grants.nih.gov/grants/guide/pa-files/PA-20-272.html". Applicants should use PA-20-272 to solicit applications through this NOSI.

Notice of Change to Key Dates for PAR-22-029 "Longitudinal Single Cell Characterization of ADRD Postmortem Tissue (R01 Clinical Trial Not Allowed)"

NOT
Tuesday, September 14, 2021
Saturday, October 23, 2021
NOT-NS-22-026

Funding Opportunity Purpose

The purpose of this notice is to extend the due date for PAR-22-029 "Longitudinal Single Cell Characterization of ADRD Postmortem Tissue (R01 Clinical Trial Not Allowed)".

Notice of Intent to Publish a Funding Opportunity Announcement for NIH Blueprint for Neuroscience Research Short Courses in Neurotherapeutics Development (R25 Clinical Trial Not Allowed)

NOT
Friday, September 10, 2021
Monday, January 1, 2024
NOT-NS-22-023

Funding Opportunity Purpose

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIH Blueprint for Neuroscience Research R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development. This FOA solicits Research Education Grant (R25) applications to develop and implement short courses on neurotherapeutics development for academic neuroscientists. The short courses should provide participants with a sufficient overview of the neurotherapeutics development process to (1) understand the steps required for therapeutics development, (2) anticipate and overcome common challenges in the process, and (3) interact effectively with collaborators who have expertise in various aspects of therapeutics development. The short courses should primarily target independent academic neuroscience researchers and senior post-doctoral fellows interested in incorporating treatment development into their research programs.

Notice of Change to Application Types Allowed for RFA-NS-21-010 "HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)"

NOT
Tuesday, September 7, 2021
Monday, January 1, 2024
NOT-NS-22-025

Funding Opportunity Purpose

The purpose of this notice is to inform applicants of a change to the Application Types Allowed for RFA-NS-21-010 "HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)". The application types have been expanded to include Resubmission applications. This change is effective as of the October 15, 2021 due date.

Notice of Change to Key Dates for RFA-NS-21-010 "HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)"

NOT
Tuesday, September 7, 2021
Monday, May 8, 2023
NOT-NS-22-021

Funding Opportunity Purpose

The purpose of this notice is to inform applicants of a change to the Key Dates for RFA-NS-21-010 "HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)".

Notice of Correction to Application and Submission Information for NOT-NS-21-068 "HEAL Initiative: Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements to Support Strategies to Advance the Study of Chronic Overlapping

NOT
Tuesday, September 7, 2021
Monday, January 1, 2024
NOT-NS-22-024

Funding Opportunity Purpose

The purpose of this notice is to correct the Application Due Date for NOT-NS-21-068 "HEAL Initiative: Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements to Support Strategies to Advance the Study of Chronic Overlapping Pain Conditions (COPCs)". Applications will be accepted through November 5, 2021, by 5:00PM local time of the applicant organization.

Notice of Change to PAR-22-026 "Selectively Target Technology Development to Understand How Changes or Dysfunction at the Capillary, Arterioles, and Small Lymphatic Vessels Level Can Have Long-term Impact on AD/ADRD (R01 Clinical Trial Not Allowed)"

NOT
Wednesday, September 1, 2021
Monday, January 1, 2024
NOT-NS-22-018

Funding Opportunity Purpose

The purpose of this notice is to inform applicants of a correction to the Letter of Intent (LOI) due date for PAR-22-026 "Selectively Target Technology Development to Understand How Changes or Dysfunction at the Capillary, Arterioles, and Small Lymphatic Vessels Level Can Have Long-term Impact on AD/ADRD (R01 Clinical Trial Not Allowed)". The LOI is due October 8, 2021; this is 30 days prior to the application due date.

The BRAIN Initiative Plan for Enhancing Diverse Perspectives (PEDP)

NOT
Tuesday, August 31, 2021
Monday, January 1, 2024
NOT-MH-21-310

Funding Opportunity Purpose

Policy notice for BRAIN Initiative PEDP. The BRAIN Initiative will include a new component in most FOAs requiring that applications include a Plan for Enhancing Diverse Perspectives (PEDP) in the proposed research.

Notice of Special Interest to Encourage Eligible NIH BRAIN Initiative Awardees to Apply for PA-21-071 Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)

Notice of Special Interest
Thursday, August 26, 2021
Monday, September 30, 2024
333
NOT-NS-22-012

Funding Opportunity Purpose

This Notice encourages eligible awardees in the BRAIN Initiative community to apply for administrative supplements in response to PA-21-071, Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed). The NIH has a strong interest in the diversity of the NIH-funded workforce (see NOT-OD-18-210) and encourages institutions to diversify their populations by enhancing the participation of individuals from groups identified as underrepresented in the biomedical, clinical, behavioral, and social sciences.

Pages